Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 6/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NEK9 | Q8TD19 | 1/20 | 0.41 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744181 | 0.86 | PDPK1 (0.46) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL4747764 | 0.77 | PDPK1 (0.42) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL4747807 | 0.76 | PDPK1 (0.44) | PDPK1TYK2ATMNEK9NEK6 | |
| SCHEMBL4745763 | 0.74 | SPIN1 (0.44) | PDPK1PDE3BPDE3A | |
| SCHEMBL4747760 | 0.72 | PDPK1 (0.56) | PDPK1TLR7PDGFRBPDGFRAKDM4E | |
| SCHEMBL30017474 | 0.71 | PDPK1 (0.46) | PDPK1ABCB1ATMTLR7PDGFRB | |
| SCHEMBL7941513 | 0.70 | TLR7 (0.56) | TLR7 | |
| SCHEMBL24355432 | 0.68 | PDPK1 (0.57) | PDPK1ABCB1MAPT | |
| SCHEMBL29756065 | 0.68 | PDPK1 (0.57) | PDPK1ABCB1MAPT | |
| SCHEMBL27355403 | 0.67 | PDE5A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008109599-A1 | PYRIMIDO [5,4-C] QUINOLINE-2, 4-DIAMINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | DCK, PDK4, PDK2 | PDPK1 6/4885ABCB1 2410/4885TYK2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.